Who has invested in Hemab?

Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Novo Seeds are named among the investors backing Hemab.

Hemab Funding: $537M Raised, IPO (2026)

Hemab funding overview

Hemab is a Biotech company based in Cambridge. Hemab has raised $537M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is an IPO announced in May 2026. The round record for Hemab runs through 2026; nothing later has been disclosed. Investors on record include Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Novo Seeds. 5 distinct backers are named across the disclosed rounds.

Hemab at a glance

Total raised: $537M
Latest round: IPO
Latest round date: May 2026
Industry: Biotech
Headquarters: Cambridge
Notable investors: Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Novo Seeds

Frequently asked about Hemab funding

How much has Hemab raised?: Hemab has raised $537M in total disclosed funding across the rounds on record.
Who has invested in Hemab?: Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Novo Seeds are named among the investors backing Hemab.
What was the latest Hemab funding round?: The most recent disclosed round is an IPO, announced in May 2026.
Where is Hemab based?: Hemab is based in Cambridge.
What sector does Hemab operate in?: Hemab is tracked under Biotech from Cambridge, with $537M in disclosed funding.
When did Hemab last raise?: The last disclosed Hemab round closed in May 2026 at IPO.

Totals shown for Hemab aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Cambridge and the investors behind them below.

Hemab Funding: $537M Raised, IPO (2026)

Hemab funding overview

Hemab at a glance

Frequently asked about Hemab funding

Hemab founders (1)

Companies related to Hemab (40)

Browse related funding lists (8)